FDA-approved product exists

Liraglutide

FDA-approved

Liraglutide has FDA-approved prescription products (LIRAGLUTIDE (ANDA212552), LIRAGLUTIDE (ANDA212972), LIRAGLUTIDE (ANDA213155), LIRAGLUTIDE (ANDA214568), LIRAGLUTIDE (ANDA215245), LIRAGLUTIDE (ANDA215421), LIRAGLUTIDE (ANDA215503), LIRAGLUTIDE (ANDA217063), LIRAGLUTIDE (ANDA217234), LIRAGLUTIDE (ANDA217590), LIRAGLUTIDE (ANDA218115), SAXENDA (NDA206321), VICTOZA (NDA022341), XULTOPHY 100/3.6 (BLA208583)). FDA's drug shortage database lists 10 Liraglutide entries (Current, To Be Discontinued) as of 2026-07-25; that describes supply of an approved product, not whether compounding is lawful. Liraglutide is not on FDA's 503B Bulks List for outsourcing facilities (list checked 2026-07-25). 50 registered ClinicalTrials.gov studies cite Liraglutide (35 completed, 4 recruiting, 4 unknown, 3 not yet recruiting, 3 terminated, 1 active not recruiting); registration is not evidence of approval, efficacy, or safety. CompoundedGuide is verifying compounding status, safety signals, and current evidence. This is not medical advice.

What we've verified

Product status: FDA-approved: LIRAGLUTIDE (ANDA212552), LIRAGLUTIDE (ANDA212972), LIRAGLUTIDE (ANDA213155), LIRAGLUTIDE (ANDA214568), LIRAGLUTIDE (ANDA215245), LIRAGLUTIDE (ANDA215421), LIRAGLUTIDE (ANDA215503), LIRAGLUTIDE (ANDA217063), LIRAGLUTIDE (ANDA217234), LIRAGLUTIDE (ANDA217590), LIRAGLUTIDE (ANDA218115), SAXENDA (NDA206321), VICTOZA (NDA022341), XULTOPHY 100/3.6 (BLA208583)
Still checking: Compounding status, shortage status, safety signals

Verified sources

openFDA Drugs@FDA P0 · retrieved 2026-07-25
openFDA Drug Shortages P0 · retrieved 2026-07-25
503B Bulks List and Interim Categories P0 · retrieved 2026-07-25
ClinicalTrials.gov API v2 P0 · retrieved 2026-07-25

Research and evidence

FDA-approved product exists cite Liraglutide. Registration is not evidence of approval, efficacy, or safety.

Browse every trial and publication for Liraglutide →

For developers

JSON record Markdown Source packet